Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;17(1):14-20.
doi: 10.2174/1570159X15666171114142422.

Noninvasive Cerebellar Stimulation as a Complement Tool to Pharmacotherapy

Affiliations
Review

Noninvasive Cerebellar Stimulation as a Complement Tool to Pharmacotherapy

Roberta Ferrucci et al. Curr Neuropharmacol. 2019.

Abstract

Background: Cerebellar ataxias represent a wide and heterogeneous group of diseases characterized by balance and coordination disturbance, dysarthria, dyssynergia and adyadococinesia, caused by a dysfunction in the cerebellum. In recent years there has been growing interest in discovering therapeutical strategy for specific forms of cerebellar ataxia. Together with pharmacological studies, there has been growing interest in non-invasive cerebellar stimulation techniques to improve ataxia and limb coordination. Both transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are non-invasive techniques to modulate cerebro and cerebellar cortex excitability using magnetic or electric fields.

Methods: Here we aim to review the most relevant studies regarding the application of TMS and tDCS for the treatment of cerebellar ataxia.

Conclusion: As pharmacological strategies were shown to be effective in specific forms of cerebellar ataxia and are not devoid of collateral effects, non-invasive stimulation may represent a promising strategy to improve residual cerebellar circuits functioning and a complement tool to pharmacotherapy.

Keywords: ataxia; cerebellar TMS; cerebellar tDCS; cerebellum; non invasive neuromodulation; tDCS..

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bird T.D. Hereditary Ataxia Overview. 1993. - PubMed
    1. Feil K., Bremova T., Muth C., Schniepp R., Teufel J., Strupp M. Update on the pharmacotherapy of cerebellar ataxia and nystagmus. Cerebellum. 2016;15(1):38–42. [http://dx.doi.org/10. 1007/s12311-015-0733-1]. [PMID: 26519380]. - PubMed
    1. Kearney M., Orrell R.W., Fahey M., Pandolfo M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst. Rev. 2012;18(4):CD007791. [PMID: 22513953]. - PubMed
    1. Li Y., Polak U., Bhalla A.D., Rozwadowska N., Butler J.S., Lynch D.R., Dent S.Y.R., Napierala M. Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich’s Ataxia. Mol. Ther. 2015;23(6):1055–1065. [http://dx.doi.org/10. 1038/mt.2015.41]. [PMID: 25758173]. - PMC - PubMed
    1. Elincx-Benizri S., Glik A., Merkel D., Arad M., Freimark D., Kozlova E., Cabantchik I., Hassin-Baer S. Clinical experience with deferiprone treatment for Friedreich ataxia. J. Child Neurol. 2016;31(8):1036–1040. [http://dx.doi.org/10.1177/0883073816636087]. [PMID: 27029487]. - PubMed

MeSH terms